Zongertinib (BI01810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers
To investigate the effects of Zongertinib, a HER2 inhibitor on different cell lines and under various conditions, we used expression data from dedicated biomarker in vivo and in vitro studies. Overall design: CDX models were generated using engineered PC-9 cells (HER2 exon 20 insertion YVMA clone 5) and  NCI-N87 cell line. Models were treated with Zongertinib (BI01810631) , while control samples were treated with Natrosol or DMSO.